Z Factor

Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.